Vertex Partnerships Target Hepatitis C | Chemical & Engineering News
Volume 90 Issue 45 | p. 13 | Concentrates
Issue Date: November 5, 2012

Vertex Partnerships Target Hepatitis C

Department: Business
Keywords: hepatitis C, partnerships, protease inhibitor

Vertex Pharmaceuticals is teaming up with Johnson & Johnson and GlaxoSmithKline in separate partnerships aimed at developing an all-oral hepatitis C treatment. Vertex and J&J’s Janssen Pharmaceuticals unit will conduct a Phase II study of a treatment combining Vertex’ polymerase inhibitor VX-135 and Janssen’s protease inhibitor simeprevir. Vertex and GSK will study a combination of VX-135 with GSK’s NS5A inhibitor GSK2336805. Last year, FDA approved Vertex’ Incivek protease inhibitor, but, like other hepatitis C drugs, it must be administered with unpleasant interferon injections.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment